232 related articles for article (PubMed ID: 16505002)
1. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
[TBL] [Abstract][Full Text] [Related]
2. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
Polito VA; Cosma MP
Am J Hum Genet; 2009 Aug; 85(2):296-301. PubMed ID: 19679226
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
[TBL] [Abstract][Full Text] [Related]
5. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).
Motas S; Haurigot V; Garcia M; Marcó S; Ribera A; Roca C; Sánchez X; Sánchez V; Molas M; Bertolin J; Maggioni L; León X; Ruberte J; Bosch F
JCI Insight; 2016 Jun; 1(9):e86696. PubMed ID: 27699273
[TBL] [Abstract][Full Text] [Related]
6. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.
Polito VA; Abbondante S; Polishchuk RS; Nusco E; Salvia R; Cosma MP
Hum Mol Genet; 2010 Dec; 19(24):4871-85. PubMed ID: 20876612
[TBL] [Abstract][Full Text] [Related]
7. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
9. Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.
Mandolfo O; Liao A; Singh E; O'leary C; Holley RJ; Bigger BW
Hum Gene Ther; 2024 Apr; 35(7-8):243-255. PubMed ID: 37427450
[TBL] [Abstract][Full Text] [Related]
10. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
[TBL] [Abstract][Full Text] [Related]
11. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
[TBL] [Abstract][Full Text] [Related]
12. FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).
Bellesso S; Salvalaio M; Lualdi S; Tognon E; Costa R; Braghetta P; Giraudo C; Stramare R; Rigon L; Filocamo M; Tomanin R; Moro E
Hum Mol Genet; 2018 Jul; 27(13):2262-2275. PubMed ID: 29648648
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
Horgan C; Jones SA; Bigger BW; Wynn R
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563245
[TBL] [Abstract][Full Text] [Related]
14. Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy.
Ellison S; Liao A; Gleitz HFE; Parker H; Booth L; Robinson J; Wood S; Taylor J; Holley R; Bigger BW
Mol Ther Methods Clin Dev; 2023 Dec; 31():101127. PubMed ID: 37920237
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
[TBL] [Abstract][Full Text] [Related]
16. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.
Braun SE; Aronovich EL; Anderson RA; Crotty PL; McIvor RS; Whitley CB
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11830-4. PubMed ID: 8265633
[TBL] [Abstract][Full Text] [Related]
17. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS).
Friso A; Tomanin R; Zanetti A; Mennuni C; Calvaruso F; La Monica N; Marin O; Zacchello F; Scarpa M
Biochim Biophys Acta; 2008 Oct; 1782(10):574-80. PubMed ID: 18675343
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
Laoharawee K; DeKelver RC; Podetz-Pedersen KM; Rohde M; Sproul S; Nguyen HO; Nguyen T; St Martin SJ; Ou L; Tom S; Radeke R; Meyer KE; Holmes MC; Whitley CB; Wechsler T; McIvor RS
Mol Ther; 2018 Apr; 26(4):1127-1136. PubMed ID: 29580682
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
